Phosphorodiamidate morpholino oligomers

See color plate.) Polymer-coated stent delivery of c-myc antisense phosphorodiamidate morpholino oligomers into swine vessels. [Pg.376]

Devi G R, Beer T M, et al. (2005). In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. 11 3930-3938. [Pg.1078]

Iversen P L (2001). Phosphorodiamidate morpholino oligomers favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. 3 235-238. [Pg.1082]

FIGURE 4.1 Chemical modifications to ribose sugar or phosphate linkages. BNA, bridged nucleic acid LNA, locked nucleic acid PMO, phosphorodiamidate morpholino oligomer. [Pg.43]

Arora V, Devi G R, Iversen P L (2004). Neutrally charged phosphorodiamidate morpholino antisense oligomers uptake, efficacy and pharmacokinetics. Curr. Pharm. Biotechnol. 5 431-439. [Pg.1078]

Hudziak RM, Barofsky E, Barofsky Dp et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation, Antisense Nucleic Acid Drug Dev 1996 6 267-272. [Pg.380]

Big Chemical Encyclopedia